|
시장보고서
상품코드
2085918
의료용 접착제 및 실란트 시장 : 제품 유형, 수지, 배합 유형, 사용성 유형, 규제 분류, 용도별 - 세계 시장 예측(2026-2032년)Medical Adhesives & Sealants Market by Product Type, Resin, Formulation Type, Usability Type, Regulatory Classification, Application - Global Forecast 2026-2032 |
||||||
360iResearch
의료용 접착제 및 실란트 시장은 2032년까지 연평균 복합 성장률(CAGR) 9.15%로 성장해 210억 3,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 113억 9,000만 달러 |
| 추정 연도(2026년) | 123억 7,000만 달러 |
| 예측 연도(2032년) | 210억 3,000만 달러 |
| CAGR(%) | 9.15% |
의료용 접착제 및 실란트는 현대의 상처 봉합, 지혈, 조직 재생, 의료기기 조립 및 최소 침습 수술에서 필수적인 요소로 자리 잡고 있습니다. 수요는 수술 건수 증가, 만성 질환 관리, 고령화, 이식형 및 웨어러블 의료기기의 이용 확대, 그리고 시술 시간 단축과 환자 편의성 향상과 같은 요구 등, 충분히 입증된 의료 동향에 의해 뒷받침되고 있습니다.
이 시장에는 외과, 치과, 상처 관리, 장루, 카테터, 전극, 진단, 경피 투여 등의 용도로 사용되는 시아노아크릴레이트, 피브린 실란트, 콜라겐계 제품, 폴리에틸렌글리콜 하이드로겔, 실리콘, 폴리우레탄, 아크릴계 및 감압 접착제가 포함됩니다. 성능에 대한 기대는 생체적합성, 무균성 확보, 내습성, 유연성, 피부 건강, 접착 내구성, 그리고 FDA, EU MDR, ISO 10993, ISO 11607, ISO 13485의 요건 준수와 점점 더 밀접하게 연관되어 있습니다.
시장 동향은 기존의 봉합사나 스테이플에서 적절한 적응증에 따라 더 신속한 적용, 조직 손상 감소, 그리고 심미적 결과의 향상을 실현하는 비침습적 봉합 기술로 전환되고 있습니다. 특히 당일 수술, 저침습 수술, 재택 회복 모델로의 전환이 진행되는 가운데, 병원이나 외래수술센터(ASC)에서는 임상적 유효성과 업무 흐름의 효율성을 모두 갖춘 제품이 우선적으로 채택되고 있습니다.
인공지능은 의료용 접착제 및 실란트의 신약 개발, 제제 개발, 제조, 규제 정보, 시판 후 조사 등 모든 단계에 영향을 미치고 있습니다. 연구 개발(R&D) 분야에서는 머신러닝을 활용함으로써 고분자 구조 스크리닝, 생체 적합성 위험 예측, 습윤 조직이나 피부가 움직이는 상태에서의 접착 거동 모델링이 가능해지며, 이를 검증된 실험실 데이터, 전임상 데이터, 임상 데이터와 결합함으로써 실험 주기를 단축할 수 있습니다.
아시아태평양에서는 중국, 인도, 일본, 한국, 호주 및 아세안(ASEAN) 시장의 병원 확장, 국내 의료기기 제조, 그리고 외과 수술에 대한 접근성 확대에 힘입어 시장이 성장하고 있습니다. 또한, 고도의 상처 치료, 당뇨병 관련 상처 관리, 선택적 수술 후 회복, 웨어러블 헬스케어 기술의 활용 확대도 이 지역에서의 보급을 뒷받침하고 있습니다. 북미에서는 확립된 임상 연구 네트워크, FDA 규제 하의 제품 승인 절차, 첨단 상처 치료의 보급, 높은 치료 기준, 그리고 웨어러블 기기, 진단 기기, 전극, 수액 세트, 원격 모니터링 시스템에 사용되는 의료기기 등급 접착제에 대한 강력한 수요 덕분에 혁신이 계속해서 활발히 이루어지고 있습니다.
아세안 지역 수요는 싱가포르, 말레이시아, 태국, 인도네시아, 베트남, 필리핀 등 각국의 병원 네트워크 확대, 의료기기의 현지 생산, 의료 관광, 그리고 외래 수술에 대한 접근성 향상과 관련이 있습니다. GCC 시장은 정부의 의료 투자, 중증 환자 전용 병원 개발, 국가 차원의 의료 개혁 프로그램, 그리고 임상적으로 검증된 상처 봉합, 지혈 및 실런트 기술에 대한 조달 우선 조치의 혜택을 받고 있습니다.
미국은 제품 혁신, 임상 도입, 그리고 FDA(미국 식품의약국) 규제에 따른 상용화 분야에서 선도적인 위치를 차지하고 있으며, 외과, 첨단 상처 치료, 웨어러블 센서, 당뇨병 관련 기기, 진단 플랫폼 등 각 분야에서 꾸준한 수요가 나타나고 있습니다. 캐나다는 품질, 안전성, 공공 조달의 가치, 그리고 증거에 기반한 도입을 중시하는 반면, 멕시코는 확립된 수출 지향형 클러스터를 통해 의료기기 제조 분야에서 그 역할을 강화하고 있습니다. 브라질은 대규모 병원 인프라와 확대되는 민간 의료 서비스 접근성을 바탕으로, 외과, 치과, 외상 및 상처 치료 제품 분야에서 라틴아메리카의 주요 수요 거점으로 자리매김하고 있습니다.
업계 리더는 명확하게 정의된 적응증에 대해 임상적 성능, 안전성, 사용 편의성 및 워크플로우상의 가치를 입증하는 근거를 마련하는 데 우선순위를 두어야 합니다. 의료용 접착제 및 실란트는 피부, 조직, 혈액, 점막은 물론 이식형 또는 웨어러블 기기와 직접 접촉하므로, 그 효능을 강력하게 입증하는 것이 매우 중요합니다. 따라서 생체적합성, 무균성, 인체공학 및 위험 관리가 시장 진입의 핵심 요소가 됩니다.
본 요약본은 의료기술평가에 따른 2차 조사 및 시장 정보의 원칙에 따라 작성되었습니다. 이러한 정보원에는 규제 체계, 동료 심사를 거친 임상 문헌, ISO 표준, 인증된 의료기기 품질 시스템, 공중보건 데이터, 병원의 조달 동향, 제품 카테고리 분석, 보험 급여 관련 고려 사항, 이상반응 모니터링 관행, 그리고 공개된 업계 정보 등이 포함됩니다.
의료용 접착제 및 실란트는 단순한 보조 제품에서 벗어나, 보다 안전하고 신속하며 저침습적인 의료를 실현하기 위한 전략적 요소로 자리매김하고 있습니다. 그 가치는 엄격한 규제, 품질, 생체적합성 요건을 충족시키면서, 폐쇄, 밀봉, 고정, 쾌적성, 감염 관리, 지혈 또는 의료기기의 성능을 향상시키는 상황에서 가장 두드러지게 발휘됩니다.
The Medical Adhesives & Sealants Market is projected to grow by USD 21.03 billion at a CAGR of 9.15% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 11.39 billion |
| Estimated Year [2026] | USD 12.37 billion |
| Forecast Year [2032] | USD 21.03 billion |
| CAGR (%) | 9.15% |
Medical adhesives and sealants are becoming essential to modern wound closure, hemostasis, tissue repair, device assembly, and minimally invasive procedures. Demand is supported by well-documented healthcare trends, including higher surgical volumes, chronic disease management, aging populations, rising use of implantable and wearable medical devices, and the need to reduce procedure time while improving patient comfort.
The market includes cyanoacrylates, fibrin sealants, collagen-based products, polyethylene glycol hydrogels, silicones, polyurethanes, acrylics, and pressure-sensitive adhesives used in surgical, dental, wound care, ostomy, catheter, electrode, diagnostic, and transdermal applications. Performance expectations are increasingly tied to biocompatibility, sterility assurance, moisture resistance, flexibility, skin integrity, adhesion durability, and compliance with FDA, EU MDR, ISO 10993, ISO 11607, and ISO 13485 requirements.
The landscape is shifting from conventional sutures and staples toward atraumatic closure technologies that support faster application, reduced tissue damage, and improved cosmetic outcomes in suitable indications. Hospitals and ambulatory surgical centers are prioritizing products that combine clinical efficacy with workflow efficiency, especially as care moves toward same-day surgery, minimally invasive procedures, and home-based recovery models.
Innovation is also accelerating in bioresorbable, antimicrobial, hydrogel, skin-friendly, and patient-wearable adhesive platforms. Manufacturers are responding to regulatory scrutiny on extractables, leachables, cytotoxicity, sensitization, irritation, and degradation products by investing in safer chemistries, stronger clinical evidence, and more robust quality management systems. Sustainability and supply resilience are gaining relevance as healthcare systems evaluate packaging waste, sterilization methods, raw material continuity, and sourcing risk.
Artificial intelligence is influencing medical adhesives and sealants across discovery, formulation, manufacturing, regulatory intelligence, and post-market surveillance. In R&D, machine learning can screen polymer structures, predict biocompatibility risks, model adhesion under wet tissue and moving-skin conditions, and shorten experimental cycles when paired with validated laboratory, preclinical, and clinical data.
In manufacturing, AI-enabled process monitoring supports defect detection, viscosity control, coating uniformity, batch consistency, sterilization assurance review, and predictive maintenance. In commercial and regulatory operations, natural language processing can help analyze complaint trends, clinical literature, adverse-event reports, usability feedback, and real-world evidence. These applications do not replace regulatory validation, but they can improve decision speed, risk detection, and product lifecycle management when governed by transparent data controls, cybersecurity safeguards, and human oversight.
Asia-Pacific is advancing through hospital expansion, domestic medical device manufacturing, and rising surgical access in China, India, Japan, South Korea, Australia, and ASEAN markets. Regional adoption is also supported by higher use of advanced wound care, diabetes-related wound management, elective surgery recovery, and wearable health technologies. North America remains innovation-intensive due to established clinical research networks, FDA-regulated product pathways, advanced wound care adoption, high procedural standards, and strong demand for device-grade adhesives used in wearables, diagnostics, electrodes, infusion sets, and remote monitoring systems.
Latin America is supported by improving private healthcare capacity, public hospital modernization, and growing procedure volumes in Brazil and Mexico, while reimbursement variability and import dependency shape adoption speed. Europe is defined by EU MDR compliance, strong specialty surgery demand, structured health technology assessment, and emphasis on biocompatibility documentation and clinical evidence. The Middle East is investing in tertiary care, medical tourism, trauma care, and hospital infrastructure, particularly in GCC markets where procurement favors validated technologies. Africa shows long-term opportunity in essential surgery, wound care, burns, and trauma care, though affordability, distribution reach, cold-chain reliability, and clinical training remain decisive factors.
ASEAN demand is linked to expanding hospital networks, medical device localization, medical tourism, and higher access to outpatient procedures in countries such as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. GCC markets benefit from government healthcare investment, high-acuity hospital development, national health transformation programs, and procurement preference for clinically validated wound closure, hemostatic, and sealant technologies.
The European Union is shaped by MDR evidence requirements, harmonized quality expectations, notified body scrutiny, sustainability pressures, and value-based healthcare procurement. BRICS countries combine large patient populations with growing domestic production capabilities and expanding surgical access, creating opportunities for cost-effective adhesives and sealants that meet international safety standards. G7 markets continue to set benchmarks for innovation, regulatory rigor, specialty surgery adoption, and premium medical device integration. NATO countries, through defense medicine, emergency preparedness, disaster response, and trauma-care priorities, sustain interest in hemostatic sealants, rapid wound closure, infection-conscious dressings, and field-ready medical technologies.
The United States leads in product innovation, clinical adoption, and FDA-governed commercialization, with strong demand across surgery, advanced wound care, wearable sensors, diabetes devices, and diagnostic platforms. Canada emphasizes quality, safety, public procurement value, and evidence-based adoption, while Mexico is strengthening its medical device manufacturing role through established export-oriented clusters. Brazil remains a key Latin American demand center for surgical, dental, trauma, and wound care products, supported by a large hospital base and expanding private healthcare access.
In Europe, the United Kingdom, Germany, France, Italy, and Spain support adoption through advanced surgical systems, specialist wound care pathways, and rigorous product evaluation, while Russia's market is influenced by localization policies, supply constraints, and changing import channels. China and India offer scale through large surgical backlogs, expanding hospital access, domestic manufacturing growth, and increasing demand for affordable advanced care products. Japan and South Korea prioritize precision, quality, biocompatibility, and advanced device integration, particularly in electronics-enabled medical wearables and high-performance materials. Australia maintains high standards for clinical governance, therapeutic goods regulation, infection prevention, and wound care innovation, supporting selective adoption of validated adhesives and sealants.
Industry leaders should prioritize evidence generation that demonstrates clinical performance, safety, usability, and workflow value in clearly defined indications. Strong claims substantiation is critical because medical adhesives and sealants interact directly with skin, tissue, blood, mucosa, and implanted or wearable devices, making biocompatibility, sterility, human factors, and risk management central to market access.
Companies should diversify raw material sourcing, qualify secondary suppliers, invest in AI-supported formulation and quality analytics, and align product development with FDA, EU MDR, ISO 10993, ISO 11607, and ISO 13485 expectations from the earliest design stage. Partnerships with surgeons, wound care specialists, hospitals, contract manufacturers, sterilization providers, and digital health companies can accelerate adoption, especially for wearable medical devices, transdermal patches, advanced dressings, ostomy systems, and minimally invasive surgical applications.
This executive summary is built on secondary research and market intelligence principles aligned with healthcare technology assessment. Inputs include regulatory frameworks, peer-reviewed clinical literature, ISO standards, recognized medical device quality systems, public health data, hospital procurement trends, product category analysis, reimbursement considerations, adverse-event monitoring practices, and publicly available industry disclosures.
The analysis triangulates demand drivers, application trends, regional adoption factors, regulatory requirements, material science developments, and technology shifts. Insights are validated through consistency checks across clinical, regulatory, technical, and commercial evidence sources, with emphasis on verifiable trends and data-backed observations rather than unsupported market-size, market-share, or forecasting claims.
Medical adhesives and sealants are moving from supporting products to strategic enablers of safer, faster, and less invasive care. Their value is strongest where they improve closure, sealing, fixation, comfort, infection control, hemostasis, or device performance while meeting strict regulatory, quality, and biocompatibility expectations.
Future competitiveness will depend on clinically differentiated formulations, resilient manufacturing, validated material performance, regional market access strategies, and responsible use of artificial intelligence. Organizations that combine material science, regulatory excellence, manufacturing discipline, and evidence-based commercialization will be best positioned to meet long-term healthcare demand.